NCT06289621
Brief Transdiagnostic Treatment for Anxiety Disorders and Post-traumatic Stress Disorder (PTSD) in South Africa
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 5 versions: 4 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 2 words Show 6 more changesShow less
- Enrollment closed, study ongoing
- Primary completion date changed from estimate of Jul 31, 2026 to Oct 9, 2026
- Study completion pushed from Dec 31, 2026 to Jun 30, 2027
- Secondary endpoints: details revised at 4 of 4 entries
- Site details revised
- Publications: details revised at 3 of 3 entries
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of May 1, 2024 to May 8, 2024
- Notable Lead sponsor: Harvard Medical School (HMS and HSDM) to Massachusetts General Hospital
- Collaborators revised (3)
- Study description shortened, about 4 words
- Study title shortened, about 3 words
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Secondary (4)
Arms and interventions
The anxiety disorders and post-traumatic stress disorder (PTSD) transdiagnostic treatment (FSET) is brief, 5-session, cognitive-behavioral intervention designed to treat symptoms associated with anxiety disorders and PTSD. The treatment is administered by lay providers (e.g., nurses) in primary care clinics in South Africa.
The enhanced standard care group is the condition. Those in the enhanced standard care control group will receive standard care plus referrals. Upon completion of the study, they will be offered the anxiety disorder and post-traumatic stress disorder treatment (FSET).
Behavioral: False Safety Behavioral Elimination Treatment (FSET), Enhanced Standard Care
Sites
1 site in 1 country
- Stellenbosch UniversityCape Town, South Africa